A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about BioCardia Inc’s (BCDA) stock grades for Value, Growth, Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
| Share Statistics | BCDA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.4 | $252.6 | 6% |
|
| Shares Out (Mil) | 10.8 | 52.3 | 22% |
|
| Institutional Ownership | 37.6% | 92.1% | 16% |
|
| Float (Mil) | 8.5 | 40.2 | 17% |
|
| Beta | 0.55 | 0.95 | 31% |
|
| Avg Daily Volume (000s) | 197 | 455 | 45% |
|
| Price Change (52-week) |
(62.4%) | 52.9% | 11% |
|
| Growth | BCDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 11.4% | (9.9%) | 57% |
|
| EPS (5yr) | 43.9% | 16.0% | 90 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (75.7%) | (15.6%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.190) | ($0.760) | ($0.600) | |
| Month Ago EPS | ($0.190) | ($0.760) | ($0.600) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.180) | ($0.710) | ($0.560) | |
| Year/Year Chg | (9.1%) | (38.4%) | (66.0%) | |
| Financials | BCDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 31% |
|
| EPS (TTM) | ($0.947) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $0 | $5 | 43% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $10 | $180 | 8% |
|
| Valuation | BCDA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BCDA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (401.0%) | (49.8%) | 1% |
|
| ROE | 601.3% | (55.5%) | 100% |
|
| Liabilities to Assets | 162.3% | 30.3% | 98% |
|
| F-Score | 3 | 3 | 19% |
|
BioCardia, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
